CD46 and CD59 Inhibitors Enhance Complement-Dependent Cytotoxicity of Anti-Cd38 Monoclonal Antibodies Daratumumab and Isatuximab in Multiple Myeloma and Other B-cell Malignancy Cells
CANCER BIOLOGY & THERAPY（2024）
Key words
Multiple myeloma,daratumumab,isatuximab,complement dependent cytotoxicity,resistance
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined